What is the prevalence of Autoimmune Lymphoproliferative Syndrome?

Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare genetic disorder characterized by abnormal lymphocyte accumulation, leading to immune dysregulation. While the exact prevalence of ALPS is not well-established, it is considered to be an extremely rare condition. The syndrome affects both males and females, typically presenting in childhood. ALPS is caused by mutations in certain genes involved in regulating lymphocyte survival, resulting in the accumulation of abnormal lymphocytes.

ALPS is characterized by various clinical manifestations, including enlarged lymph nodes and spleen, autoimmune cytopenias (such as anemia, thrombocytopenia), and an increased risk of lymphoma. The severity and specific symptoms can vary among individuals. Diagnosis of ALPS involves clinical evaluation, laboratory tests, and genetic analysis.

Due to its rarity, the prevalence of ALPS is difficult to determine precisely. However, it is estimated to affect fewer than 1 in 1 million individuals worldwide. As a rare disorder, ALPS often requires specialized medical expertise for accurate diagnosis and management. Ongoing research aims to improve understanding of ALPS and develop targeted therapies to address the immune dysregulation associated with the condition.